NCT01614405 - Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions

Primary Biliary Cirrhosis

Interventions

DRUG

TDF/FTC/LPV/r

one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur

DRUG

Placebo

6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.

Trial Locations (1)

T6G 2B2

University of Alberta, Edmonton